Academy of Physicians
in Clinical Research

Academy of Physicians
in Clinical Research

News from SCRIP

APCR Members can get a free trial to SCRIP and a discount on a SCRIP subscription by contacting John Lezcano from SCRIP directly at the information below. 

John Lezcano
Corporate Account Manager

Pharma intelligence | informa
T: (212) 652-2678
M: (631) 807-4971

Rare Disease Roundtable: How Rare Is Too Rare?

Mon, 04/01/2019 - 2:02pm

Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at...

      Related Stories 

Finance Watch: Arteaus Comes Full Circle As Investors Monetize Emgality Royalties

Mon, 04/01/2019 - 12:50pm

Arteaus sells royalty stream from Lilly's Emgality giving investors a $260m payday. Also, Pfizer spin-out SpringWorks nabs another $125m, Arch...

      Related Stories 

Merck KGaA Plays Down Mavenclad Label And $99,500 annual Price For 10 MS Pills

Mon, 04/01/2019 - 9:32am

Merck KGaA's multiple sclerosis pill Mavenclad has finally won FDA approval, but some analysts think its US label, stipulating second-line...

      Related Stories 

Novartis Dives Into Inflammasome Pool With IFM Tre Purchase

Mon, 04/01/2019 - 6:27am

The Swiss major has bought a US biotech that specializes in targeting the NLRP3 pathway in a deal valued at...

      Related Stories 

After Abeta Blow, Biogen And Eisai Get BACE Boost

Mon, 04/01/2019 - 6:01am

Elenbecestat can continue in the Phase III MISSION AD studies in Alzheimer’s, the data safety monitoring board says.

      Related Stories 

Pipeline Watch: Bumper Crop Of Product Approvals In Japan

Mon, 04/01/2019 - 5:51am

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical...

      Related Stories 

India Unbranded Generics Plans An Industry Threat As Elections Loom?

Sun, 03/31/2019 - 11:29pm

As national elections loom, India’s prime minister has said the government will expand a retail scheme to sell cut-price no-name...

      Related Stories 

Galapagos Flies As Filgotinib Soars In FINCH Studies

Sun, 03/31/2019 - 11:04am

More evidence of its strong safety profile suggests that the Belgian biotech's oral selective JAK1 inhibitor partnered with Gilead will...

      Related Stories 

Tricida Ready For FDA Filing With Long-Term Safety, Efficacy Data In CKD

Fri, 03/29/2019 - 12:51pm

Not only did Tricida’s Phase III long-term extension study show safety for TRC101 in CKD metabolic acidosis patients, but also...

      Related Stories 

Start-Up Mitochon's Repurposed Drug Targets Mitochondria For Orphan Diseases

Fri, 03/29/2019 - 12:37pm

Emerging Company Profile: Mitochon Pharmaceuticals, founded in 2014, focuses on mitochondrial therapeutics with emphasis on neurodegenerative diseases. CEO Robert Alsonso...

      Related Stories 

Asia Deal Watch: Takeda On A Deal Spree

Fri, 03/29/2019 - 12:30pm

Takeda has inked three deals in recent days: a cancer antibody-drug conjugate partnership, a PI3K out-license and a nanomedicine drug-delivery...

      Related Stories 

Secarna’s Antisense Sweet Spot Offers Deal And IPO Prospects

Fri, 03/29/2019 - 6:01am

Jonas Renz, managing director of antisense platform company Secarna, discussed deal making and the company’s outlook in an interview at the...

      Related Stories 

Choose Carefully For China Drug Development Success: White Paper

Thu, 03/28/2019 - 10:38pm

By avoiding crowded space and focusing instead on therapeutic areas with large potential, China remains attractive for drug developers, notes...

      Related Stories